Fund shareholders of CRISPR Therapeutics AG
ISIN CH0334081137 · Switzerland · LEI 506700O6IRRIQLT3W370
- Fund shareholders
- 222
- Of which ETFs
- 55 167 other funds
- Value held
- 1.5B $ 717.9K € · 12.2M SEK
| Fund | Shares | Value | Weight in fund | |
|---|---|---|---|---|
| BlackRock Advantage SMID Cap V.I. Fund BlackRock Variable Series Funds, Inc. | 300 | 14.3K $ | 0.01 % | as of Mar 31, 2026 ↗ |
| PGIM Balanced Fund Prudential Investment Portfolios, Inc. | 300 | 14.3K $ | 0.00 % | as of Mar 31, 2026 ↗ |
| Avantis Responsible U.S. Equity ETF American Century ETF Trust | 289 | 17.4K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| Amplify Small-Mid Cap Equity ETF Amplify ETF Trust | 232 | 11K $ | 0.90 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 231 | 11K $ | 0.09 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 199 | 9.5K $ | 0.07 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 167 | 8.7K $ | 0.11 % | as of Apr 30, 2026 ↗ |
| JPMorgan Fundamental Data Science Small Core ETF J.P. Morgan Exchange-Traded Fund Trust | 136 | 6.5K $ | 0.09 % | as of Mar 31, 2026 ↗ |
| Sector Rotation Fund Meeder Funds | 122 | 5.8K $ | 0.01 % | as of Mar 31, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 119 | 5.7K $ | 0.10 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 89 | 5.4K $ | 0.02 % | as of Feb 28, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 87 | 4.1K $ | 0.14 % | as of Mar 31, 2026 ↗ |
| Avantis Inflation Focused Equity ETF American Century ETF Trust | 80 | 4.8K $ | 0.05 % | as of Feb 28, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 27 | 1.6K $ | 0.15 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 23 | 1.1K $ | 0.04 % | as of Mar 31, 2026 ↗ |
| Goldman Sachs MSCI World Private Equity Return Tracker ETF Goldman Sachs ETF Trust | 21 | 1.3K $ | 0.00 % | as of Feb 28, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 223.1K € | 0.27 % | as of Dec 31, 2025 ↗ | |
| PATRIVAL, FI PATRIVALOR, SGIIC, S.A. | 178.6K € | 0.27 % | as of Dec 31, 2025 ↗ | |
| PATRIBOND, FI PATRIVALOR, SGIIC, S.A. | 178.6K € | 0.23 % | as of Dec 31, 2025 ↗ | |
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 86.3K € | 2.35 % | as of Dec 31, 2025 ↗ | |
| MERCH-EUROUNION, FI ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 33.5K € | 0.74 % | as of Dec 31, 2025 ↗ | |
| SLM ICEBERG, SICAV, S.A. ANDBANK WEALTH MANAGEMENT, SGIIC, S.A.U. | 17.9K € | 0.13 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| ARK Genomic Revolution ETF ARK ETF Trust | 8.91 % | as of Apr 30, 2026 ↗ |
| American Beacon ARK Transformational Innovation Fund AMERICAN BEACON FUNDS | 6.19 % | as of Mar 31, 2026 ↗ |
| ARK Innovation ETF ARK ETF Trust | 4.98 % | as of Apr 30, 2026 ↗ |
| Global X Genomics & Biotechnology ETF GLOBAL X FUNDS | 3.48 % | as of Feb 28, 2026 ↗ |
| AXS Green Alpha ETF INVESTMENT MANAGERS SERIES TRUST II | 3.41 % | as of Mar 31, 2026 ↗ |
| Jacob Small Cap Growth Fund Jacob Funds Inc. | 2.77 % | as of Feb 28, 2026 ↗ |
| Horizon Kinetics Medical ETF Listed Funds Trust | 2.53 % | as of Mar 31, 2026 ↗ |
| A&P LIFESCIENCE FUND, FI WELZIA MANAGEMENT, SGIIC, S.A. | 2.35 % | as of Dec 31, 2025 ↗ |
| WisdomTree BioRevolution Fund WisdomTree Trust | 1.87 % | as of Mar 31, 2026 ↗ |
| iShares Genomics Immunology and Healthcare ETF iShares Trust | 1.80 % | as of Apr 30, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 215 | -1 | 30,122,571 | -4.0 % |
| 2026Q1 | 216 | -4 | 31,392,582 | +2.4 % |
| 2025Q4 | 220 | +41 | 30,648,910 | +1.2 % |
| 2025Q3 | 179 | +45 | 30,285,730 | +17.2 % |
| 2025Q2 | 134 | -7 | 25,849,853 | -9.8 % |
| 2025Q1 | 141 | -7 | 28,659,857 | +6.6 % |
| 2024Q4 | 148 | -8 | 26,894,945 | +1.5 % |
| 2024Q3 | 156 | +3 | 26,502,647 | +2.5 % |
| 2024Q2 | 153 | +3 | 25,862,741 | +0.7 % |
| 2024Q1 | 150 | -9 | 25,675,654 | +0.6 % |
| 2023Q4 | 159 | 25,525,269 |
Funds holding the debt of CRISPR Therapeutics AG
16 funds declare 16 bond lines of this company. The amount is the one the fund files. It is not a share of the debt, because no regulator publishes the amount outstanding in open access.
Cite this page
Titelia. "Fund shareholders of CRISPR Therapeutics AG". https://titelia.com/en/stocks/crispr-therapeutics-ag-CH0334081137